Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864059 | 0.89 | L3MBTL1 (0.46) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14493826 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2ABCB1ALOX5PTGS2BCHE | |
| SCHEMBL7281853 | 0.87 | CA12 (0.55) | SMN1; SMN2ABCB1ALOX5PTGS2ABCG2 | |
| SCHEMBL1254108 | 0.86 | TAAR1 (0.61) | SMN1; SMN2KMT2AABCB1CA12CA1 | |
| SCHEMBL7559310 | 0.85 | KMT2A (0.53) | SMN1; SMN2KMT2AABCB1BCHEABCG2 | |
| SCHEMBL12844541 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AABCB1ALOX5PTGS2 | |
| SCHEMBL21753882 | 0.84 | AOC3 (0.44) | SMN1; SMN2KMT2AALOX5KDM4EALDH1A1 | |
| SCHEMBL2518861 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2ACA12CA1CA2 | |
| SCHEMBL16953073 | 0.82 | KMT2A (0.51) | SMN1; SMN2KMT2AALOX5PTGS2BCHE | |
| SCHEMBL29175409 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AABCB1BCHEABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SMN1; SMN2 1371/4885KMT2A 2987/4885ABCB1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.